

## SHORT COMMUNICATION

©Shkrigunov et al.

### IDENTIFICATION OF PROTEIN COMPONENTS OF THE TRANSFORMATION SYSTEM IN THE CELL LINE OF IMMORTALIZED HUMAN KERATINOCYTES HaCaT EXPOSED TO SURFACTANTS

*T.S. Shkrigunov\*, N.E. Vavilov, N.F. Samenkova, Yu.S. Kisrieva,  
A.L. Rusanov, D.D. Romashin, I.I. Karuzina, A.V. Lisitsa, N.A. Petushkova*

Institute of Biomedical Chemistry,  
10 Pogodinskaya str., Moscow, 119121 Russia; \*e-mail: shkrigunov05@mail.ru

Using the method of shotgun mass spectrometry, we have evaluated changes in the proteomic profile of HaCaT cells in response to the treatment with sodium dodecyl sulfate (anionic surfactant) and Triton-X100 (non-ionic surfactant) in two concentrations (12.5 µg/ml and 25.0 µg/ml). The study revealed induction of orphan CYP2S1 (biotransformation phase I) in response to Triton-X100. We have identified proteins of II (glutathione-S-transferases, GSTs) and III (solute carrier proteins, SLCs) biotransformation phases, as well as antioxidant proteins (peroxiredoxins, PRDXs; catalase, CAT; thioredoxin, TXN). Thus, proteins of all three xenobiotic detoxification phases were detected. The presented results suggest a new prospect of using HaCaT keratinocytes as a model of human epidermis for studying the metabolism of drugs/toxicants in human skin *in vitro*.

**Key words:** immobilized HaCaT keratinocytes; surfactants; Triton X-100; LC-MS/MS; cytochrome P450 2S1

**DOI:** 10.18097/PBMC20247001061

## INTRODUCTION

This work is a continuation of our studies on applicability of the HaCaT cell line as a test system for chemical proteomics problems based on mass spectrometry. We have previously shown that HaCaT keratinocytes, as a model of the human epidermis, can be used for characterization of toxicity of chemical compounds, for example, surfactants of various structures [1–3].

One of the goals of chemical proteomics is the identification of interactions between small molecules and proteins forming the entire cellular proteome, including identification of particular proteins/metabolic pathways involved in transformation of xenobiotics [4]. The main organs of xenobiotic metabolism in the human body include the liver, kidneys, lungs, and intestine [5]. The skin has not been considered for a long time in the context of the metabolism of foreign substances, despite the fact that it is the largest organ of the human body exposed to many external aggressive factors [6]. However, in addition to its barrier function, the skin can also metabolize xenobiotics. For example, biotransformation enzymes such as cytochromes P450 (CYPs), flavin monooxygenases, glutathione-S-transferases,

N-acetyltransferases and sulfotransferases have been found in the mammalian epidermis, although with relatively low specific activity [6, 7].

The risks of xenobiotics and mechanisms of their action are frequently evaluated using animal models. However, animal models are often poor predictors of human response due to differences in physiology and immunity. In addition, modern requirements for the pharmaceutical and cosmetics industry require the reduction and replacement of animals in experiments [8]. Therefore, various keratinocyte, fibroblast, or melanocyte-based models, including HaCaT (spontaneously immortalized human keratinocyte cell line), are currently used to evaluate the safety of various substances in relation to human health. A characteristic feature of HaCaT cells is their unlimited division capacity, which determines the possibility of obtaining a standardized research object [9].

The goal of this work was mass spectrometric identification of keratinocyte HaCaT proteins associated with the biotransformation of xenobiotics. As in our previous works, sodium dodecyl sulfate (anionic surfactant, AIS) and Triton X-100 (non-ionic surfactant, NIS) have been chosen as model toxicants, which are used in scientific research and

*Abbreviations used:* AIS – anionic surfactants; BSA – bovine serum albumin; CAT – catalase; CYPs – cytochromes P450; DTT – dithiothreitol; EDTA – ethylenediaminetetraacetic acid; GSTs – glutathione-S-transferases; HPLC – high performance liquid chromatography; NIS – non-ionic surfactants; NSAF – normalized spectral abundance factor; PMSF – phenylmethylsulfonyl fluoride; PRDXs – peroxiredoxins; TCEP – trichlorethyl phosphate; TEAB – triethylammonium bicarbonate; TFA – trifluoroacetic acid; Tris – tris(hydroxymethyl)aminomethane; SLCs – solute transport proteins; TXN – thioredoxin.

certification tests as a positive control in determining cytotoxicity [3]. In addition, these AIS and NIS are used in almost any type of liquid, paste and powder cleaning products, and are also included in pharmaceuticals and feed additives as stabilizers, solvents, and emulsifiers.

## MATERIALS AND METHODS

### *Reagents*

The following reagents have been used in this work: sodium dodecyl sulfate, Triton X-100, bovine serum albumin (Merck, Germany); modified lyophilized trypsin from porcine pancreas (Promega, USA); trifluoroacetic acid (Fluka, Germany); acetonitrile, dithiothreitol; deionized water (Acros, USA); 2,2-bicinchoninic acid (Pierce, USA), as well as chemically pure reagents from local suppliers.

### *Cultivation of HaCaT Cells*

Cells of the immortalized cell line HaCaT (CLS Cell Lines Service, Germany, 300493) were seeded in 75 cm<sup>2</sup> flasks (Corning, USA). Their cultivation was carried out in DMEM/F12 1:1 medium (PanEco, Russia) containing 10% FBS and antibiotics (100 units/ml penicillin and 100 mg/ml streptomycin), in a CO<sub>2</sub> incubator (at 37±1°C, humidity 90±10%, CO<sub>2</sub> content of 5.0±1.0%). After reaching 60–70% confluency, the culture medium was removed, and the cells were exposed to solutions of AIS (25.0 µg/ml), NIS1 (12.5 µg/ml), or NIS2 (25.0 µg/ml) in a nutrient medium. Fresh nutrient medium was added to control samples. The cells were exposed to AIS or NIS1/NIS2 for 48 h.

After cultivation the cells were dispersed with 3 ml of trypsin-EDTA solution (PanEco) incubated for 3 min at 37°C to dissociate from the surface of the culture flasks; the cell sediment was washed 2–3 times with potassium phosphate buffer, pH 7.4, and centrifuged at 10,000 g for 20 min (4°C).

### *Preparation of Protein Extracts and Trypsinolysis in Solution*

In order to obtain sufficient amounts of the HaCaT protein for proteomic analysis, we pooled cells from three culture flasks, representing three biological replicates for each group (control, AIS-exposed, or NIS-exposed) in one tube for further processing.

The HaCaT sediment was resuspended in 400 µl of cold H<sub>2</sub>O containing the protease inhibitor PMSF (1%); the aqueous cell suspensions were then homogenized in an ice bath using ultrasound: two cycles of 25 s, 20 kHz with an interval between cycles of 25 s (Sonoplus HD2070, BANDELIN Electronic, Germany) and then centrifuged at 14,000 g for 20 min (4°C). The resulting supernatant was collected, and the supernatant protein content

was determined using 2,2-bicinchoninic acid at 562 nm (8453 UV-visible spectrophotometer, Agilent, USA), using BSA as a standard.

HaCaT cell extracts (175 µg protein per sample) were subjected to tryptic digestion as described previously [10]. Denaturation of proteins and reduction of disulfide bonds was carried out using a reducing solution containing 87 mM DTT and 6.7 mM TCEP in denaturing buffer (12 mM sodium deoxycholate, 2 M thiourea, 2.5 mM EDTA and 75 mM Tris-HCl, pH 8.5); samples were incubated at 42°C for 60 min under constant stirring in a GFL Shaking Incubator 3032 (GFL, Germany). The ratio of the reducing solution to the protein sample was 1:1 (v/v). Then an alkylating buffer (100 µl of denaturing buffer, 10 µl of 4-vinylpyridine, and 90 µl of N,N-dimethylformamide, pH<9.0) was added to each sample (the ratio of alkylating solution volume to sample volume was 1:12). After thorough mixing the reaction mixture was incubated at 20°C for 60 min in the dark.

After the incubation, digestion buffer containing 100 mM CaCl<sub>2</sub> and 42 mM triethylammonium bicarbonate (TEAB, 42 µl) in H<sub>2</sub>O (water for UV, HPLC, ACS) was added (up to 100 µl). Trypsin was added to the sample at a trypsin:protein ratio of 1:100 and then incubated in the dark at 44°C under stirring (50 rpm) for 120 min in a GFL Shaking Incubator 3032. Then another portion of trypsin (11.4 µl) was added and samples were incubated in the dark at 37°C under stirring (50 rpm) for 120 min in the same incubator. Enzymatic digestion was stopped by adding formic acid to a final concentration of 1%, and then the samples were centrifuged at room temperature (30 min, 10,000 g). Digested peptide mixtures were analyzed without further processing using liquid chromatography coupled to LC-MS/MS.

### *LC-MS/MS Analysis*

One microgram of peptides (1–4 µl) was applied to an Acclaim µ-Precolumn (0.5 mm × 3 mm, particle size 5 µm, Thermo Fisher Scientific, USA) at the loading rate 10 µl/min for 4 min. Elution was carried out in the isocratic mode using the mobile phase C (2% acetonitrile, 0.1% formic acid). The peptide mixture was then separated using high performance liquid chromatography (Ultimate 3000 Nano LC System, Thermo Fisher Scientific) on a 15 cm long C<sub>18</sub> column (Acclaim PepMap RSLC 75 µm i.d., Thermo Fisher Scientific). Next, the peptides were eluted with a gradient of buffer B (80% acetonitrile, 0.1% formic acid) at a flow rate of 0.3 µl/min. The total analysis time was 90 min. This included initial equilibration of the column with buffer A (0.1% formic acid) for 4 min, then the concentration of buffer B was linearly increased from 5% to 35% (60 min) and within 6 min to 99%. After a 10-minute wash with 99% buffer B, its concentration was linearly reduced to the initial 2% (6 min). Finally, the analytical column was equilibrated with buffer A for 5 min.

Mass spectrometry analysis was performed using a Q Exactive HF-X mass spectrometer (Thermo Fisher Scientific) as previously described [10].

For proteins of the HaCaT keratinocytes (control and after exposure to surfactants), 21 MS/MS spectra were obtained in the “.raw” format, which were then converted into MGF files using the ProteoWizard MSConvert program [11]. The files were imported into the SearchGUI platform (v. 3.3.17) [12] and analyzed using the X!Tandem and MS-GF+ search algorithms against the SwissProt database (v. 1.4.2019, FASTA format) for the species *Homo sapiens*. The search was carried out using a database of inverted and random amino acid sequences (decoy), the percentage of false positive results (false discovery rate, FDR)  $\leq 1\%$ . The search parameters included: digestive enzyme — trypsin; the maximum number of possible missed trypsin cleavage sites was 1; fixed modification — pyridylethylation of cysteine; variable modification — oxidation of methionine; accuracy of measuring the theoretical and experimental mass of the peptide  $\pm 5$  ppm; accuracy of measurement of theoretical and experimental mass of fragment ions  $\pm 0.01$  Da; the value of the charge state of the peptide ions was “2+, 3+, and 4+”. The PeptideShaker integrator [13] was used to produce an Excel spreadsheet file with protein identification results. The dataset is available at Mendeley Data, DOI: 10.17632/45w5hbhp6.1.

### Data Processing

The statistical significance of the differences between the compared parameters was evaluated using the Student's *t*-test for independent sets. For control HaCaT cells, the set consisted of 6 technical replicates (mass spectra), in the case of HaCaT keratinocytes treated with AIS the set consisted of 9 technical replicates, and 3 technical replicates each for NIS1 and NIS2, respectively. Data are presented as mean (M)  $\pm$  standard deviation (SD). The results were considered as statistically significant at a threshold level of statistical significance (alpha level) of 0.05.

To quantify protein content, the NSAF (normalized spectral abundance factor) algorithm was chosen because of its high reproducibility. Using NSAF values it possible to compare protein content within a sample and/or between samples [14].

## RESULTS AND DISCUSSION

To identify specific proteins/metabolic pathways involved in metabolism of various types of xenobiotics in the human epidermis, a comparative analysis of the proteomes of control HaCaT cells and cells exposed to surfactants was carried out. A total of four lists of identified proteins were obtained. These

included control, AIS, NIS1, and NIS2. Lists of proteins identified in the work are presented in Supplementary Materials (Tables S1-S4).

According to the recommendations of the HUPO Committee (Human Proteome Organization), protein identification is considered reliable when at least two proteotypic peptides are detected [15]. As a result, in total we have identified  $803 \pm 129$  proteins. At the same time,  $460 \pm 154$  proteins were identified in control HaCaT keratinocytes. After exposure to AIS, a slight increase in the number of identifications was observed —  $553 \pm 150$ . However, the comparison did not reveal statistical differences between the number of proteins identified in control and AIS-treated cells ( $p > 0.20$ ). After exposure to NIS1 and NIS2, a small and statistically insignificant ( $p > 0.05$ ) decrease in the number of identified proteins was found as compared to the control ( $410 \pm 111$  and  $406 \pm 110$  proteins, respectively).

For identification of proteins involved in cellular detoxification and metabolism of drugs and xenobiotics in the HaCaT cells the corresponding lists of human proteins were extracted from the Gene Ontology database [16]. Comparison of the obtained lists with the HaCaT cell proteomes before and after exposure to surfactants resulted in identification of 18 proteins involved in cellular detoxification and metabolism of xenobiotics (Table 1). At the same time, in the control cells and cells exposed to NIS, almost the same number of proteins was identified: 13 and 14 proteins, respectively. Exposure to AIS and NIS1 led to a slight increase in the number of identified proteins responsible for the biotransformation of xenobiotics (15 and 17, respectively).

Only eleven common proteins (61%) involved in the biotransformation of xenobiotics were found for control HaCaT cells and the cells exposed to AIS, NIS1, and NIS2. These included: SLC7A5, GSTK1, GSTP1, GSTO1, PRDX3, CAT, TXN, PRDX6, PRXL2A, PRDX5, PRDX1 (Table 1). The content of five proteins (GSTK1, GSTP1, PRDX3, CAT, TXN), assessed by the values of the normalized spectral abundance factor NSAF [14], increased in response to AIS as compared to the control (Table 1). Among these proteins, PRDX6 attracts much interest because its activation protects keratinocytes from cell death under stress conditions induced by reactive oxygen species *in vitro* and *in vivo* [17]. In contrast to AIS, the effect of NIS1 and NIS2 on HaCaT keratinocytes had virtually no effect on the NSAF values of the proteins GSTK1, GSTP1, PRDX3, CAT, and TXN as compared to the control.

Biotransformation of xenobiotics is a complex process involving a large number of enzymes; this process consists of three phases: activation (phase I), detoxification (phase II), and excretion (phase III). A key role in the detoxification of numerous compounds,

**IDENTIFICATION OF BIOTRANSFORMATION PROTEINS IN HaCaT CELLS**

*Table 1.* The list of identified proteins in HaCaT keratinocytes involved in the xenobiotic metabolism and cellular detoxification

##	Identifier	Gene	Protein name	Number of validated peptides/spectra					Normalized spectral abundance factor (NSAF)			
				Control	AIS*	NIS1**	NIS2***	Control	AIS	NIS1	NIS2	
1	Q01650	SLC7A5	Large neutral amino acids transporter small subunit 1	3/16	2/14	2/10	2/8	0.061	0.050	0.038	0.031	
2	P16152	CBR1	Carbonyl reductase [NADPH] 1	4/10	ND	6/14	5/11	0.041	ND	0.058	0.045	
3	Q9Y2Q3	GSTK1	Glutathione S-transferase kappa 1	4/14	6/26	3/9	5/15	0.064	0.128	0.053	0.074	
4	P78417	GSTO1	Glutathione S-transferase omega 1	3/17	4/21	2/9	2/6	0.096	0.119	0.051	0.034	
5	P00390	GSR	Glutathione reductase, mitochondrial	ND	1/1	1/1	ND	ND	0.003	0.003	ND	
6	P09211	GSTP1	Glutathione S-transferase pi 1	11/60	14/154	11/89	11/57	0.397	1.020	0.589	0.378	
7	P04179	SOD2	Superoxide dismutase [Mn], mitochondrial	ND	1/7	1/3	1/1	ND	0.042	0.018	0.006	
8	Q96SQ9	CYP2S1	Cytochrome P450 2S1	ND	ND	ND	3/5	ND	ND	ND	0.006	
9	P14550	AKR1A1	Aldo-keto reductase family 1 member 1A1	ND	6/15	4/8	ND	ND	0.055	0.028	ND	
10	P53985	SLC16A1	Monocarboxylate transporter 1	ND	ND	1/1	ND	ND	ND	0.005	ND	
11	A0A0A0MRQ5	PRDX1	Peroxioredoxin 1	5/44	7/55	7/30	4/16	0.271	0.349	0.182	0.099	
12	P32119	PRDX2	Peroxioredoxin 2	4/23	7/39	5/15	ND	0.113	0.229	0.081	ND	
13	P30048	PRDX3	Peroxioredoxin 3	1/8	2/10	3/11	4/12	0.009	0.049	0.054	0.059	
14	P30044	PRDX5	Peroxioredoxin 5	7/30	10/52	6/8	5/10	0.158	0.274	0.042	0.053	
15	P30041	PRDX6	Peroxioredoxin 6	7/27	10/97	10/44	8/19	0.139	0.500	0.227	0.098	
16	Q9BRX8	PRL2A	Peroxioredoxin-like 2A	3/5	2/3	5/7	6/13	0.031	0.019	0.044	0.082	
17	P04040	CAT	Catalase	2/4	6/10	2/5	5/9	0.009	0.023	0.012	0.021	
18	P10599	TXN	Thioredoxin	5/49	8/156	6/61	5/20	0.511	1.660	0.645	0.213	

ND – not determined; \* AIS – anionic surfactant (sodium dodecyl sulfate, 25.0 µg/ml); \*\* NIS1 – nonionic surfactant (Triton X-100, 12.5 µg/ml); \*\*\* NIS2 – nonionic surfactant (Triton X-100, 25.0 µg/ml).

both of endogenous and exogenous origin, belongs to enzymes of the CYP superfamily. Most drugs used in dermatology are either CYP substrates, or inducers, or inhibitors. The main site of metabolism of these compounds in the skin is keratinocytes, which are characterized by a low level of CYP mRNA expression. In the skin of all animal species and *in vitro* skin systems, the content of CYPs is very low or they are not even detectable [18].

Using mass spectrometry analysis we were able to detect a CYP belonging to family 2, subfamily S (CYP2S1) in the immortalized human keratinocyte cell line HaCaT exposed to NIS2. According to the GeneCards database, CYP2S1 is a participant in the interconnected metabolic pathways “Oxidation by cytochrome P450” and “Metapathway biotransformation Phase I and II”. Using the SearchGUI platform, we have identified three corresponding CYP2S1 peptides with a high degree of confidence (the scoring confidence index was 100%, Table 2). Table 3 shows the theoretically possible and identified (marked in bold) fragment ions of the peptide <sup>251</sup>QVQQHQGNLDASGPARG specific for cytochrome 2S1 (CYP2S1).

Previously, induction of CYP2S1 in the HaCaT cells was detected only as expression of the protein-coding gene based on an increase in the mRNA level in response to exposure to ultraviolet radiation [19]. The NeXtProt human proteome project database also does not contain information about the presence of CYP2S1 in keratinocytes at the protein level [20].

CYP2S1 belongs to the so called orphan CYPs, which are known to be expressed predominantly in extrahepatic tissues but have no defined function with endogenous or exogenous substrates [21]. Maximum expression of CYP2S1 is observed in the epithelium of tissues exposed to the external environment, such as the respiratory and digestive tracts and skin [22].

From the data in Table 1 it follows that in HaCaT cells four proteins of phase II of xenobiotic metabolism belonging to the glutathione S-transferase (GST) family were identified, including the main skin glutathione S-transferase pi 1 (GST P09211, GSTP1).

In our samples of HaCaT keratinocytes, two transporter proteins of phase III of xenobiotic biotransformation were detected (Table 1). SLC7A5 was identified in all four studied samples

Table 2. The list of peptides identified in HaCaT keratinocytes using the SearchGUI platform and belonging to the orphan cytochrome P450 2S1 (CYP2S1)

##	Amino acid sequence	m/z exper.	charge	m/z error (mln <sup>-1</sup> )	Significance
1	<sup>251</sup> QVQQHQGNLDASGPARG	569,62	3+	2,53	100
2	<sup>144</sup> EGEELIQAEAR	622,81	2+	1,20	100
3	<sup>89</sup> EALGGQAEFFSGR	675,82	2+	2,96	99

Table 3. Theoretically possible and identified (shown in bold) fragment ions of the peptide <sup>251</sup>QVQQHQGNLDASGPARG specific for cytochrome 2S1 (CYP2S1)

	b+	b++	b-H <sub>2</sub> O	b+-H <sub>2</sub> O	b-NH <sub>3</sub>	b+-NH <sub>3</sub>	Seq	y	y++	y-H <sub>2</sub> O	y+-H <sub>2</sub> O	y-NH <sub>3</sub>	y+-NH <sub>3</sub>	
1	129.066	65.037	129.066	65.037	129.066	65.037	<b>Q</b>							16
2	228.134	114.571	228.134	114.571	228.134	114.571	<b>V</b>	1577.778	789.393	1577.778	789.393	1577.778	789.393	15
3	356.193	178.600	356.193	178.600	356.193	178.600	<b>Q</b>	1478.709	739.858	1478.709	739.858	1478.709	739.858	14
4	484.251	242.629	484.251	242.629	484.251	242.629	<b>Q</b>	1350.651	675.829	1350.651	675.829	1350.651	675.829	13
5	621.310	311.159	621.310	311.159	621.310	311.159	<b>H</b>	1222.592	611.800	1222.592	611.800	1222.592	611.800	12
6	749.369	375.188	749.369	375.188	749.369	375.188	<b>Q</b>	1085.533	543.270	1085.533	543.270	1085.533	543.270	11
7	806.390	403.699	806.390	403.699	806.390	403.699	<b>G</b>	957.475	479.241	957.475	479.241	957.475	479.241	10
8	920.433	460.720	920.433	460.720	920.433	460.720	<b>N</b>	900.453	450.730	900.453	450.730	900.453	450.730	9
9	1033.517	517.262	1033.517	517.262	1033.517	517.262	<b>L</b>	786.410	393.709	786.410	393.709	786.410	393.709	8
10	1148.544	574.776	1148.544	574.776	1148.544	574.776	<b>D</b>	<b>673.326</b>	337.167	<b>673.326</b>	337.167	<b>673.326</b>	337.167	7
11	1219.581	610.294	1219.581	610.294	1219.581	610.294	<b>A</b>	<b>558.299</b>	279.653	<b>558.299</b>	279.653	<b>558.299</b>	279.653	6
12	1306.613	653.810	1306.613	653.810	1306.613	653.810	<b>S</b>	<b>487.262</b>	244.135	<b>487.262</b>	244.135	<b>487.262</b>	244.135	5
13	1363.635	682.321	1363.635	<b>682.321</b>	1363.635	682.321	<b>G</b>	<b>400.230</b>	200.619	<b>400.230</b>	200.619	<b>400.230</b>	200.619	4
14	1460.688	730.847	1460.688	730.847	1460.688	730.847	<b>P</b>	343.209	172.108	<b>343.209</b>	172.108	343.209	172.108	3
15	1531.725	766.366	1531.725	766.366	1531.725	766.366	<b>A</b>	246.156	123.582	246.156	123.582	246.156	123.582	2
16							<b>R</b>	175.119	88.063	175.119	88.063	175.119	88.063	1

of HaCaT cells, while SLC16A1 was detected only in HaCaT keratinocytes treated with NIS1 (by 1 peptide). In addition, it turned out that while the effect of AIS had virtually no effect on the protein content, both NIS1 and NIS2 led to a some decrease in the NSAF SLC7A5 value (approximately 2 times, Table 1).

Comparison of the content of proteins involved in phase I (CYP2S1) and phase II (GSTK1 and GSTP1) biotransformation reactions in NaCaT cells treated with NIS2 showed that the NSAF values for these GSTs significantly exceeded the NSAF value for CYP2S1 (Table 1). This is consistent with the literature data that the activity/expression of phase II biotransformation enzymes such as GST and glucuronosyltransferases is much higher than the activity/expression of CYP. It is believed that the high content of GST conjugating enzymes, primarily responsible for detoxification, means that the skin may be protected from reactive metabolites generated by CYP [23].

It is known that the induction of some CYPs can be accompanied by an increase in the content of antioxidant enzymes, including such known antioxidant catalysts as: catalase, SOD, and peroxidases [24]. As can be seen from Table 1, an increase in the content of catalase (CAT), which, along with peroxiredoxins, is classified as a phase II protein of xenobiotic metabolism [25], was registered not only after exposure to NIS2, but also to AIS.

Thus, analysis of the proteomes of HaCaT cells (a model of human skin epidermis) has shown that HaCaT keratinocytes contain proteins involved in all three phases of xenobiotic detoxification.

## CONCLUSIONS

Currently, *in vitro* toxicology methods and approaches using cell cultures are widely used to study the effects of drugs and toxic compounds as an alternative to animal experiments. The human keratinocyte cell line HaCaT (a model of human skin epidermis) is often used to assess the safety of various substances in relation to human health. A characteristic feature of HaCaT cells is their unlimited division capacity, which determines the possibility of obtaining a standardized research object.

An assessment of the possibility of using human keratinocytes of the HaCaT cell line as a test system for studying the processes of biotransformation of xenobiotics was carried out using surfactants — sodium dodecyl sulfate (AIS) and Triton X100 (NIS), which are used in the practice of certification tests as a positive control in the method for determining cytotoxicity. There were no noticeable differences in the amount of identified proteins in HaCaT keratinocytes before and after exposure to AIS and NIS. The response of the HaCaT keratinocyte proteome depended on the nature of the effect. In particular,

induction of orphan cytochrome P450 2S1 was detected in response of HaCaT cells to treatment with 25.0 µg/ml NIS (Triton X100). In addition, phase II (glutathione-S-transferases, GSTs) and phase III (transporter proteins, SLCs) proteins of biotransformation reactions, as well as the antioxidant proteins (peroxiredoxins, PRDXs; catalase, CAT; thioredoxin, TXN), were identified. Thus, the immortalized human keratinocyte cell line HaCaT can be an effective test model for *in vitro* toxicology experiments.

## ACKNOWLEDGMENTS

Mass spectrometry analysis was carried out using the equipment of the “Human Proteome” Core Facility at the Institute of Biomedical Chemistry (Russia).

## FUNDING

The work was performed within the framework of the Program for Basic Research in the Russian Federation for a long-term period (2021–2030) (No. 122030100170-5).

## COMPLIANCE WITH ETHICAL STANDARDS

This article does not contain any research involving humans or the use of animals as objects.

## CONFLICT OF INTEREST

The authors declare no conflicts of interest.

*Supplementary materials are available in the electronic version at the journal site (pbmc.ibmc.msk.ru).*

## REFERENCES

1. Petushkova N.A., Rusanov A.L., Zgoda V.G., Pyatnitski M.A., Larina O.V., Nakhod K.V., Luzgina N.G., Lisitsa A.V. (2017) Proteome of the human HaCaT keratinocytes: Identification of the oxidative stress proteins after sodium dodecyl sulphate exposur. *Mol. Cell Biol.*, **51**(5), 748-758. DOI: 10.1134/S0026893317050259
2. Kisrieva Y.S., Samenkova N.F., Larina O.V., Zgoda V.G., Karuzina I.I., Rusanov A.L., Luzgina N.G., Petushkova N.A. (2020) Comparative study of the human keratinocytes proteome of the HaCaT line: Identification of proteins encoded by genes of 18 chromosomes under the influence of detergents. *Biomeditsinskaya Khimiya*, **66**(6), 469-476. DOI: 10.18097/PBMC20206606469
3. Shkrigunov T., Kisrieva Y., Samenkova N., Larina O., Zgoda V., Rusanov A., Romashin D., Luzgina N., Karuzina I., Lisitsa A., Petushkova N. (2022) Comparative proteoinformatics revealed the essentials of SDS impact on HaCaT keratinocytes. *Sci. Rep.*, **12**, 21437. DOI: 10.1038/s41598-022-25934-4

4. Fedorov I.I., Lineva V.I., Tarasova I.A., Gorshkov M.V. (2020) Mass spectrometry-based chemical proteomics for drug target discoveries. *Biochemistry (Moscow)*, **87**(9), 983-994. DOI: 10.31857/S0320972522090056
5. Oesch F., Fabian E., Oesch-Bartlomowicz B., Werner C., Landsiedel R. (2007) Drug-metabolizing enzymes in the skin of man, rat, and pig. *Drug Metab. Rev.*, **39**(4), 659-698. DOI: 10.1080/03602530701690366
6. Svensson C.K. (2009) Biotransformation of drugs in human skin. *Drug Metab. Dispos.*, **37**(2), 247-253. DOI: 10.1124/dmd.108.024794
7. Baron J.M., Höller D., Schiffer R., Frankenberg S., Neis M., Merk H.F., Jugert F.K. (2001) Expression of multiple cytochrome P450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. *J. Invest. Dermatol.*, **116**(4), 541-548. DOI: 10.1046/j.1523-1747.2001.01298.x
8. Portugal-Cohen M., Cohen D., Kohen R., Oron M. (2023) Exploitation of alternative skin models from academia to industry: Proposed functional categories to answer needs and regulation demands. *Front. Physiol.*, **14**, 1215266. DOI: 10.3389/fphys.2023.1215266
9. Ramadan Q., Ting F.C.W. (2016) *In vitro* micro-physiological immune-competent model of the human skin. *Lab Chip*, **16**(10), 1899-1908. DOI: 10.1039/c6lc00229c
10. Shkrigunov T., Pogodin P., Zgoda V., Larina O., Kisrieva Y., Klimenko M., Latyshkevich O., Klimenko P., Lisitsa A., Petushkova N. (2022) Protocol for increasing the sensitivity of MS-based protein detection in human chorionic villi. *Curr. Issues Mol. Biol.*, **44**(5), 2069-2088. DOI: 10.3390/cimb44050140
11. ProteoWizard Home Page. Retrieved May 22, 2023, from: <https://proteowizard.sourceforge.io>
12. Vaudel M., Barsnes H., Berven F.S., Sickmann A., Martens L. (2011) SearchGUI: An open-source graphical user interface for simultaneous OMSSA and X!Tandem searches. *Proteomics*, **11**(5), 996-999. DOI: 10.1002/pmic.201000595
13. Vaudel M., Burkhardt J.M., Zahedi R.P., Oveland E., Berven F.S., Sickmann A., Martens L., Barsnes H. (2015) PeptideShaker enables reanalysis of MS-derived proteomics data sets. *Nat. Biotechnol.*, **33**(1), 22-24. DOI: 10.1038/nbt.3109
14. McIlwain S., Mathews M., Bereman M., Rubel E., MacCoss M., Noble W.S. (2012) Estimating relative abundances of proteins from shotgun proteomics data. *BMC Bioinform.*, **13**, 308. DOI: 10.1186/1471-2105-13-308
15. Human Proteome Project Mass Spectrometry Data Interpretation Guidelines Version 3.0.0. Retrieved February 20, 2024, from: [https://hupo.org/resources/Documents/HPPMSDataGuidelines\\_3.0.0.pdf](https://hupo.org/resources/Documents/HPPMSDataGuidelines_3.0.0.pdf)
16. du Plessis L., Skunca N., Dessimoz C. (2011) The what, where, how and why of gene ontology — a primer for bioinformaticians. *Brief. Bioinformatics*, **12**(6), 723-735. DOI: 10.1093/bib/bbr002
17. Kümin A., Huber C., Rulicke T., Wolf E., Werner S. (2006) Peroxiredoxin 6 is a potent cytoprotective enzyme in the epidermis. *Am. J. Pathol.*, **169**(4), 1194-1205. DOI: 10.2353/ajpath.2006.060119
18. Oesch F., Fabian E., Landsiedel R. (2018) Xenobiotica-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models. *Arch. Toxicol.*, **92**(8), 2411-2456. DOI: 10.1007/s00204-018-2232-x
19. McNeilly A.D., Woods J.A., Ibbotson S.H., Wolf C.R., Smith G. (2011) Characterisation of a human keratinocyte HaCaT cell line model to study the regulation of cytochrome P450 CYP2S1. *Drug Metab. Dispos.*, **40**(2), 283-289. DOI: 10.1124/dmd.111.042085
20. Zahn-Zabal M., Michel P., Gateau A., Nikitin F., Schaeffer M., Audot E., Gaudet P., Duek P., Teixeira D., Rech de Laval V., Samarasinghe K., Bairoch A., Lane L. (2020) The neXtProt knowledgebase in 2020: Data, tools and usability improvements. *Nucleic Acids Res.*, **48**(D1), D328-D334. DOI: 10.1093/nar/gkz995
21. Rivera S.P., Saarikoski S.T., Hankinson O. (2002) Identification of a novel dioxin-inducible cytochrome P450. *Mol. Pharmacol.*, **61**(2), 255-259. DOI: 10.1124/mol.61.2.255
22. Smith G., Wolf C.R., Deeni Y.Y., Dawe R.S., Evans A.T., Comrie M.M., Ferguson J., Ibbotson S.H. (2003) Cutaneous expression of cytochrome P450 CYP2S1: Individuality in regulation by therapeutic agents for psoriasis and other skin diseases. *Lancet*, **361**(9366), 1336-1343. DOI: 10.1016/S0140-6736(03)13081-4
23. Couto N., Newton J.R.A., Russo C., Karunakaran E., Achour B., Al-Majdoub Z.M., Sidaway J., Rostami-Hodjegan A., Clench M.R., Barber J. (2021) Label-free quantitative proteomics and substrate-based mass spectrometry imaging of xenobiotic metabolizing enzymes in *ex vivo* human skin and a human living skin equivalent model. *Drug Metab. Dispos.*, **49**(1), 39-52. DOI: 10.1124/dmd.120.000168
24. Thum T., Erpenbeck V., Moeller J., Hohlfeld J.M., Krug N., Borlak J. (2006) Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. *Environ. Health Perspect.*, **114**(11), 1655-1661. DOI: 10.1289/ehp.8861
25. Fekry M.I., Xiao Y., Berg J.Z., Guengerich F.P. (2019) A role for the orphan human cytochrome P450 2S1 in polyunsaturated fatty acid  $\omega$ -1 hydroxylation using an untargeted metabolomic approach. *Drug Metab. Dispos.*, **47**(11), 1325-1332. DOI: 10.1124/dmd.119.089086

Received: 25. 01. 2024.

Revised: 15. 02. 2024.

Accepted: 16. 02. 2024.

**ИДЕНТИФИКАЦИЯ БЕЛКОВ-КОМПОНЕНТОВ СИСТЕМЫ ТРАНСФОРМАЦИИ  
В КЛЕТОЧНОЙ ЛИНИИ ИММОРТАЛИЗОВАННЫХ КЕРАТИНОЦИТОВ ЧЕЛОВЕКА HaCaT,  
ПОДВЕРГНУТЫХ ВОЗДЕЙСТВИЮ ПОВЕРХНОСТНО-АКТИВНЫХ ВЕЩЕСТВ**

*Т.С. Шкригунов\*, Н.Э. Вавилов, Н.Ф. Саменкова, Ю.С. Кисриева, А.Л. Русанов,  
Д.Д. Ромашин, И.И. Карузина, А.В. Лисица, Н.А. Петушкова*

Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича,  
119121, Москва, ул. Погодинская, 10; \*эл. почта: shkrigunov05@mail.ru

Методом панорамной масс-спектрометрии проведена оценка изменений белкового профиля клеток HaCaT в ответ на воздействие поверхностно активных веществ (ПАВ) разной природы — додецилсульфата натрия (ПАВ анионного типа — АПАВ) и Тритона X-100 (неионный ПАВ — НПАВ) в двух концентрациях — 12,5 мкг/мл (НПАВ 1) и 25,0 мкг/мл (НПАВ 2). Была зарегистрирована индукция орфанного CYP2S1 (I фаза биотрансформации) в ответ на воздействие НПАВ2. Среди белков II и III фаз биотрансформации, были идентифицированы глутатион-S-трансферазы (GSTs) и белки-транспортёры растворённых веществ (SLCs) соответственно, а также белки-антиоксиданты (пероксиредоксины, PRDXs; каталаза, CAT; тиоредоксин, TXN). Таким образом, мы обнаружили белки всех трёх фаз детоксикации ксенобиотиков. Представленные результаты указывают на возможность использования иммортализованной клеточной линии кератиноцитов человека HaCaT в качестве модели эпидермиса кожи для оценки уровня индукции белков, участвующих в процессах биотрансформации токсикантов в коже человека *in vitro*.

*Полный текст статьи на русском языке доступен на сайте журнала (<http://pbmc.ibmc.msk.ru>).*

**Ключевые слова:** иммобилизованные кератиноциты человека линии HaCaT; поверхностно-активные вещества; Тритон X-100; LC-MS/MS; цитохром P450 2S1

**Финансирование.** Работа выполнена в рамках Программы фундаментальных научных исследований в Российской Федерации на долгосрочный период (2021–2030 годы) (№ 122030100170-5).

Поступила в редакцию: 25.01.2024; после доработки: 15.02.2024; принята к печати: 16.02.2024.